[Tokyo December 21, 2023] Corundum Systems Biology Inc., a group company of Corundum Innovation Co., Ltd. and a Japanese company that brings together microbiome research and business creation, has newly invested in the field of women’s reproductive health. Corundum’s latest investment is part of the Series A funding, led by Sofinnova Partners and OMX Ventures, that raised a total of USD38 million for Freya Biosciences. Freya is a clinical-stage startup dedicated to advancing women’s reproductive immunotherapies. Freya utilizes vaginal microbial immunotherapeutics for the treatment of infertility in women with dysbiotic vaginal microbiota who are undergoing assisted reproductive technology (ART), including in vitro fertilization (IVF).
Corundum Systems Biology will also support the business development of Freya Biosciences in Japan and Korea, where demand for IVF is particularly high.
For more information, visit here.
About Corundum Innovation
Corundum Innovation Co., Ltd., and Corundum Ventures Ltd. (Hereafter Corundum) provide venture capital (VC) investment and consulting services to investors for both financial and strategic returns. Corundum provides flexible services to COIF’s investors for new business development in various phases with our expertise in science, technology, business development, corporate management, finance and consulting, as well as our strong network with top Israeli VC and the valuable information we can access through fund activities. Corundum’s support includes information gathering, negotiation for partnership, direct investment, market development, HR development, and fund formation.
Corundum Innovation Co., Ltd.